And you thought their focus was in #drugs. Valeant #Pharmaceuticals shows us there a different way to do business.

Valeant Pharmaceuticals isn't going to break any records in the drug discovery race, and frankly I don't think could care less. Last year Valeant's CEO Michael Pearson succeeded in 11 out 13 take over bids, not a bad batting average. Drug discovery is clearly not their focus with Valeant spending less than 5% of their revenue on R&D. They prefer …